Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Tables)

v3.5.0.2
Condensed Consolidated Financial Statements Detail (Tables)
6 Months Ended
Jun. 30, 2016
Condensed Consolidated Financial Statements Detail [Abstract]  
Accrued and other liabilities

Accrued and other liabilities consisted of the following (in thousands):

 

 

 

June 30,

 

 

December 31,

 

 

 

2016

 

 

2015

 

Accrued payroll and other benefits

 

$

1,627

 

 

$

2,156

 

Accrued clinical trial costs

 

 

1,451

 

 

 

406

 

Accrued incentive compensation

 

 

915

 

 

 

2,609

 

Deferred rent

 

 

757

 

 

 

608

 

Accrued legal and accounting fees

 

 

299

 

 

 

517

 

Other

 

 

688

 

 

 

729

 

Total

 

$

5,737

 

 

$

7,025

 

 

Outstanding securities considered anti-dilutive

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share of common stock (in thousands):

 

 

 

Three  Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

Common stock options and RSUs

 

 

9,345

 

 

 

8,362

 

 

 

9,476

 

 

 

7,850

 

Warrants for common stock

 

 

18,331

 

 

 

19,087

 

 

 

18,280

 

 

 

19,087

 

Total

 

 

27,676

 

 

 

27,449

 

 

 

27,756

 

 

 

26,937